

Browse News

Category

Any

Sub-Category

Any

Conference

Any

Year

Any

Browse

LATEST News: Understanding how people respon_

SHARE     Subscribe

ecancer News


Conference News

The body's defence mechanisms: Teamwork is key for cancer-fighting proteins

29 Oct 2018

The mechanisms that orchestrate the functions of our bodies and keep us healthy are quite complex, involving critical molecular components that are still poorly understood.

The journal *Nature Communications* has published recent research on this topic by a team led by Dr. El Bachir Affar, a professor in the Department of Medicine, Faculty of Medicine at the Université de Montréal and researcher at the Centre de Recherche de l'Hôpital Maisonneuve-Rosemont.



Their work highlighted the crucial role played by a very specific protein, known as BAP1, in preventing cancer from developing.

This discovery was made in collaboration with several other teams, including the one headed by the co-principal investigator, Dr. Marc Therrien, a professor in the Department of Pathology and Cell Biology, Faculty of Medicine at the Université de Montréal and researcher at the Institute for Research in Immunology and Cancer (IRIC).

Decades of research have shown that each of our cells is like a factory employing thousands of workers (who are, in this case, active proteins with highly specific roles and clearly defined life spans).

Inside each cell, proteins communicate with one another so they can carry out their respective functions in perfect harmony.

Any disruption in the way they work could lead to serious illnesses such as cancer.

BAP1 plays a key role in protecting cells against cancer development—but, like other proteins, this tumour-suppressor can stop working properly.

In fact, BAP1 defects are seen in many types of cancer, including mesothelioma, melanoma and renal cell carcinoma.

For example, BAP1 malfunctions have been found in one half of patients suffering from mesothelioma, a particularly deadly form of cancer.

Dr. Affar's team had previously shown that BAP1 needs partners to remain operational and effectively protect cells, but the exact molecular mechanism of how it works remained unknown.

Using advanced scientific techniques, Dr. Affar's and Dr. Therrien's teams were able to gain a better understanding of certain tumour suppression mechanisms, revealing the molecular symbiosis between BAP1 and its partner ASXL2.

This mutually beneficial relationship helps protect cells and, as a result, keep organs cancer-free.

This research helps us understand how proteins work together and identifies critical protein communication points where breakdowns can lead to cancer.

These insights could lead to new cancer diagnosis and treatment strategies, which could in turn significantly improve survival rates among patients with mesothelioma or other cancers.

Understanding how communication failures between BAP1 and ASXL2 manifest at the molecular level could make personalised medicine possible.

Source: [University of Montreal](#)

Related news

Understanding how people respond to symptoms of a brain tumour
(22 Mar 2019)

Mailing colorectal cancer screening kit found effective, regardless of financial incentive
(22 Mar 2019)

Discovery may lead to precision-based strategy for triple negative breast cancer
(22 Mar 2019)

How 'sleeping cell' cancer stem cells are maintained in chronic myelogenous leukaemia
(22 Mar 2019)

Study gives new perspective on production of blood cells and immune cells
(22 Mar 2019)

Origin of resistance to lung cancer drug discovered
(22 Mar 2019)

Comments

You must [login](#) to post comments

New Comment >

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our [Privacy Policy](#).

Related videos



New developments in soft tissue and bone sarcoma research
21.03.19 ★★★★★




The epidemiological shift of cancer
21.03.19 no rating ★



Progress and prospects of the EORTC
21.03.19 no rating ★



The importance of the patient voice in clinical trials
21.03.19 no rating ★



Latest updates in melanoma research
21.03.19 no rating ★

Disease areas

- Brain & nervous system
- Breast
- Colorectal & gastro
- Haematology oncology
- Head & neck
- Hepatobiliary pancreatic
- Lung & pleura
- Melanoma & skin
- Neuroendocrine
- Ovary & gynaecology
- Paediatric
- Prostate & urology
- Sarcomas
- Bone

Patient Care

- Complementary medicine
- Elderly
- Nursing
- Nutrition & wellbeing
- Palliative
- Patient empowerment
- Personalised medicine
- Psychosocial

Policy

- Care
- Economics
- Global health & cancer
- Low-middle income
- Medicines
- Organisation of cancer
- Prevention
- R&D
- Regulatory
- Science domains
- Social determinants
- Technology & innovation
- Training & development

Prevention & Screening

- Bioinformatics
- Biology
- Biomarkers
- Causes of cancer
- Control, survivorships & outcomes
- Detection, diagnosis & prognosis
- R&D
- Regulatory
- Science domains
- Social determinants
- Technology & innovation
- Training & development

Treatments

- Antibodies & immunotherapy
- Cell therapy & stem cells
- Complications
- Cytotoxics
- Drug development
- Hormones/endocrine
- Radiotherapy
- Supportive care
- Surgery
- Targeted molecules
- Transplantation
- Vaccines & virus

Founding partners



Founding Charities



Published by

